GlassScriptPhysician profile
Ibrahim K El-Abbassi
NPI 1316946262
$3,282.53
in general payments reported to CMS, 2019-2025
14 companies · $461 in 2025
The $461 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $464 · 2020: $262 · 2021: $144 · 2022: $343 · 2023: $1,472 · 2024: $136 · 2025: $461.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $1,229 · Food and Beverage: $841.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $1,229.00 |
| Food and Beverage | $840.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,429.01 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $529.19 | 2019-2025 | Tezspire, Fasenra |
| Glaxosmithkline, LLC. | $516.69 | 2019-2025 | Nucala, Trelegy Ellipta |
| United Therapeutics Corporation | $157.02 | 2025 | Tyvaso |
| Viatris Specialty LLC | $135.43 | 2025 | Yupelri |
| Sunovion Pharmaceuticals INC. | $115.17 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.61 | 2019 | |
| Intuitive Surgical, INC. | $92.12 | 2024 | |
| Genentech USA, INC. | $55.30 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $52.18 | 2019-2023 | Dupixent |
| Actelion Pharmaceuticals US, INC. | $29.99 | 2024 | Uptravi, Opsumit |
| Mylan Specialty L.P. | $20.39 | 2019 | |
| Grifols USA, LLC | $19.05 | 2019 | |
| Insmed, INC. | $16.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ibrahim El-Abbassi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.